Why the UAE’s Medical Device Classification System is a Game-Changer for U.S. Healthtech Companies
Why the UAE’s Medical Device Classification System is a Game-Changer for U.S. Healthtech Companies The United Arab Emirates (UAE) has quietly built one of the world’s most innovation-friendly pathways for medical device companies—and now, more than ever, U.S.-based healthtech startups and scaleups should take notice. Unlike the FDA’s formal and risk-heavy classification system, the UAE’s Ministry of Health and Prevention (MOHAP) offers a flexible, product-specific, and internationally harmonized framework that accelerates market access, reduces cost, and creates entry into a health-conscious, tech-forward region. This is not just an alternative to the U.S. regulatory maze—it’s a springboard into the broader Middle East, Africa, and Asia. UAE vs. FDA: Key Differences at a Glance Criteria FDA (USA) MOHAP / UAE Classification Class I, II, III Class I, IIa, IIb, III (EU MDR aligned) Approach Risk-based Risk-based + product-specific Timeline 12–36 months Weeks to classification...